Cost-effectiveness of hetrombopag, eltrombopag, and avatrombopag for chronic immune thrombocytopenia in China: a cost-utility analysis
Under current pricing, hetrombopag represents the most cost-effective second-line TPO-RA for adult chronic ITP in China. It dominates eltrombopag and offers a favorable economic profile compared with avatrombopag. These findings support the use of hetrombopag as a preferred option in resource-limited settings.
Authors
- Yao Jin
- Wang Lv (ORCID: https://orcid.org/0009-0007-2014-0480)
- Zhujin Song (ORCID: https://orcid.org/0009-0003-1122-9994)
- Melody V. Wu (ORCID: https://orcid.org/0000-0002-5246-2659)
- Zhengqiang Hu
- Su Zeng
- Shanshan Jin
Institutions
- Zhejiang International Studies University (CN)
- Children's Hospital of Zhejiang University (CN)
- Center for Clinical Research (United States) (US)
- Zhejiang University (CN)
Publication Details
- Journal
- Frontiers in Public Health
- Published
- 2026-02-19
- DOI
- https://doi.org/10.3389/fpubh.2026.1763592
- Primary Topic
- Platelet Disorders and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Zhejiang Pharmaceutical Association